ResMed scrambles to warn healthcare providers and revise its labeling after trial data showed its sleep apnea treatment increased the risk of death in patients with symptomatic chronic heart failure.
ResMed (NYSE:RMD) disclosed that a Phase III trial testing 1 of its sleep apnea devices on patients with symptomatic chronic heart failure didn't meet primary endpoints and actually increased the risk of death.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1cxeUZ0
Cap comentari:
Publica un comentari a l'entrada